The 66th
Scientific Meeting
초록접수 미리보기
| 18S-048 |
Risk of cancer after herpes zoster
Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
BACKGROUND
Whether the cancer risk increases in patients with herpes zoster (HZ) is controversy. The aim of our study is to investigate the association between HZ disease and cancer incidence.
Methods
The study was based on a retrospective cohort in the National Health Insurance data of South Korea. Between 2002-2015, individuals over 20 years old, with a herpes zoster diagnosis were matched to individuals without a herpes zoster diagnosis by sex, age and CCI (Charlson comorbidity index). Risk of cancer following zoster was assessed by generating hazard ratios using Cox regression.
Results
In total 81993 patients for each group. Herpes zoster patients had no increased risk of developing cancer (HR = 0.95, 95%CI = 0.921-0.985, P = 0.0048). When categorized by cancer subdivision, risks of malignancy in oropharynx (HR = 0.41, 95%CI = 0.336-0.509, P = 0) and GI tract (HR = 0.86, 95%CI = 0.813-0.925 P = 0) are decreased but those of thyroid (HR = 1.2, 95%CI = 1.074-1.342, P = 0.001) and hematologic (HR = 1.66,95%CI = 1.357-2.035, P = 0) malignancy are increased.
Conclusion
The risk of thyroid and hematological cancer increases in patients with HZ.
Whether the cancer risk increases in patients with herpes zoster (HZ) is controversy. The aim of our study is to investigate the association between HZ disease and cancer incidence.
Methods
The study was based on a retrospective cohort in the National Health Insurance data of South Korea. Between 2002-2015, individuals over 20 years old, with a herpes zoster diagnosis were matched to individuals without a herpes zoster diagnosis by sex, age and CCI (Charlson comorbidity index). Risk of cancer following zoster was assessed by generating hazard ratios using Cox regression.
Results
In total 81993 patients for each group. Herpes zoster patients had no increased risk of developing cancer (HR = 0.95, 95%CI = 0.921-0.985, P = 0.0048). When categorized by cancer subdivision, risks of malignancy in oropharynx (HR = 0.41, 95%CI = 0.336-0.509, P = 0) and GI tract (HR = 0.86, 95%CI = 0.813-0.925 P = 0) are decreased but those of thyroid (HR = 1.2, 95%CI = 1.074-1.342, P = 0.001) and hematologic (HR = 1.66,95%CI = 1.357-2.035, P = 0) malignancy are increased.
Conclusion
The risk of thyroid and hematological cancer increases in patients with HZ.
|
|
